和黃醫藥(00013.HK)於內地展開抗腫瘤藥物臨床試驗
和黃醫藥(00013.HK)公布,在中國展開一項HMPL-A83的I期臨床試驗,首名患者已於今日(15日)接受給藥治療。HMPL-A83是一種研究性的新型 IgG4型人源化抗CD47單克隆抗體。
和黃醫藥首席執行官兼首席科學官蘇慰國博士表示,HMPL-A83是由公司自有的創新藥研發平台發現和開發的第十三個創新抗腫瘤藥物,並且具有豐富的潛力與現有的小分子藥物聯合使用分,對推進HMPL-A83的開發感到非常振奮。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.